{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Diagnostics",
      "Epidemiology",
      "Human cancer",
      "KRAS mutation",
      "Tumor progression"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32725342",
  "DateCompleted": {
    "Year": "2021",
    "Month": "07",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s10555-020-09915-5"
    ],
    "Journal": {
      "ISSN": "1573-7233",
      "JournalIssue": {
        "Volume": "39",
        "Issue": "4",
        "PubDate": {
          "Year": "2020",
          "Month": "Dec"
        }
      },
      "Title": "Cancer metastasis reviews",
      "ISOAbbreviation": "Cancer Metastasis Rev"
    },
    "ArticleTitle": "Molecular epidemiology and diagnostics of KRAS mutations in human cancer.",
    "Pagination": {
      "StartPage": "1029",
      "EndPage": "1038",
      "MedlinePgn": "1029-1038"
    },
    "Abstract": {
      "AbstractText": [
        "RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most frequently mutated followed by NRAS. The emblematic KRAS mutant cancers are pancreatic, colorectal, lung adenocarcinomas and urogenital cancers. KRAS mutation frequencies are relatively stable worldwide in various cancer types with the one exception of lung adenocarcinoma. The frequencies of KRAS variant alleles appears cancer type specific, reflecting the various carcinogenic processes. In addition to point mutation KRAS, allelic imbalances are also frequent in human cancers leading to the predominance of a mutant allele. KRAS mutant cancers are characterized by typical, cancer-type-specific co-occurring mutations and distinct gene expression signatures. The heterogeneity of KRAS mutant primary cancers is significant, affecting the variant allele frequency, which could lead to unpredictable branching development in metastases. Selection of minute mutant subclones in the primary tumors or metastases during target therapies can also occur frequently in lung or colorectal cancers leading to acquired resistance. Ultrahigh sensitivity techniques are now routinely available for diagnostic purposes, but the proper determination of mutant allele frequency of KRAS in the primary or metastatic tissues may have larger clinical significance."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "2nd Department of Pathology, Semmelweis University, Budapest, Hungary. jtimar@gmail.com."
          }
        ],
        "LastName": "Timar",
        "ForeName": "Jozsef",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostic and Research Institute of Pathology, Medical University of Graz, Auenbruggerpl. 2, 8036, Graz, Austria."
          }
        ],
        "LastName": "Kashofer",
        "ForeName": "Karl",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Cancer Metastasis Rev",
    "NlmUniqueID": "8605731",
    "ISSNLinking": "0167-7659"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "KRAS protein, human"
    },
    {
      "RegistryNumber": "EC 3.6.5.2",
      "NameOfSubstance": "Proto-Oncogene Proteins p21(ras)"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genes, ras"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Epidemiology"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Proto-Oncogene Proteins p21(ras)"
    }
  ]
}